NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE"

Transcription

1 NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Clinical evidence review of everolimus for refractory partial-onset seizures associated with tuberous sclerosis complex NHS England Unique Reference Number 1700 / NICE ID001 FOR PUBLIC CONSULTATION (17 January 2018) First published: [Feb 2018] Updated: [Not ] Prepared by: National Institute for Health and Care Excellence on behalf of NHS England Specialised Commissioning About this clinical evidence review Clinical evidence reviews provide a summary of the best available evidence for a single technology within a licensed indication for which the responsible commissioner is NHS England. The clinical evidence review supports NHS England in producing clinical policies but is not NICE guidance or advice. NHS URN 1700 / NICE ID001 Clinical evidence review for everolimus for refractory seizures associated with TSC Page 1 of 65

2 Summary Evidence review The focus of this review is on everolimus (Votubia, Novartis Pharmaceuticals) as adjunctive treatment of patients aged 2 years and older who have refractory partial-onset seizures associated with tuberous sclerosis complex (TSC).The evidence review was undertaken in line with NHS England s methods for undertaking clinical evidence reviews. A literature search was undertaken, which identified 329 references (see appendix 2 for search strategy). The company also provided a submission of evidence. Seven studies were included in the review; six published studies and one currently unpublished study of the phase III extension study (Franz, in press). Results Evidence of the effect of everolimus comes from one 12-week double-blinded, placebo-controlled randomised control trial (RCT) including 366 patients (French, 2016), together with a long-term (up to 48 months) uncontrolled extension study of that trial (Franz, in press). Patients in these studies had a confirmed diagnosis of tuberous sclerosis complex and epilepsy that was not responding to treatment with antiepileptic drugs (AED). Five additional studies with smaller sample sizes (6-20 patients) also provide evidence. Effectiveness Evidence from the 12-week regulatory trial (French, 2016) suggests that both low exposure and high exposure everolimus, when given as adjunctive therapy to between 1 and 3 AEDs, are associated with a statistically significantly greater reduction in seizure frequency than placebo (28.2% [low exposure everolimus], 40.0% [high exposure everolimus] and 15.1% [placebo]). Evidence from the phase III extension study (Franz et al. in press) indicates that the benefit improves over time (in the extension study, the percentage of people with a reduction in seizure frequency of at least 50% was 31% at week 18, 46.6% at 1 year and 57.7% at 2 years of treatment with NHS URN 1700 / NICE ID001 Page 2 of 65

3 everolimus (these preceding data will be included in Franz et al., but have already been presented in a poster and therefore are not considered academic-in-confidence). Franz et al is a publication which covers the extension period of the original study. The unpublished results from Franz et al. have been taken into account by the policy working group based on a confidential draft of the article which was provided by the company. This will be published in the near future and will be available at the time a commissioning policy is considered for routine commissioning. There is limited evidence of a difference in behavioural outcomes, and changes in AED usage from additional studies. Safety and tolerability Evidence from the extension study, which studied 361 patients up to 2 years, indicates that the most frequent treatment-related adverse effects were stomatitis (33.5%), mouth ulceration (26.0%), diarrhoea (10.5%), aphthous ulcer (10.2%), and pyrexia (10.2%). The occurrence of adverse effects did not increase over time. The unpublished safety and tolerability data from Franz et al. (in press) has been taken into account by the policy working group as a confidential draft of the article which was provided by the company. This will be published in the near future and will be available at the time a commissioning policy is considered for routine commissioning. Evidence gaps The patients included in the registration trial and extension study (French, 2016 and Franz, in press) had a high baseline seizure rate (34.5 to 42 seizures in a 28 day period) and almost half of the included patients had not gained seizure control after treatment with 6 or more previous AEDs. In NHS clinical practice, the disease is considered refractory after at least 2 appropriate AEDs, given at a therapeutic dose, have not resulted in a reduction in seizure frequency and severity. Furthermore, the majority (>80%) of patients were aged under 18 years (median age 10.1 years [range 2.2 years to 56.3 years]); the marketing authorisation permits use in those aged 2 years and older. NHS URN 1700 / NICE ID001 Page 3 of 65

4 None of the included studies provide evidence of everolimus in comparison with surgery, vagus nerve stimulation (VNS) or the ketogenic diet. NHS URN 1700 / NICE ID001 Page 4 of 65

5 Table of contents Summary... 2 Evidence review...2 Introduction... 7 Disease background...7 Focus of review...8 Epidemiology...9 Product overview Treatment pathway and current practice Evidence review Identification of studies Results Evidence gaps Relevance to NICE guidelines and NHS England policies References Appendix 1 Patient and carer submission... Error! Bookmark not defined. Appendix 2 Search strategy Appendix 3 Study selection Appendix 4 Evidence tables Appendix 5 Results tables Appendix 6 Grading of the evidence base NHS URN 1700 / NICE ID001 Page 5 of 65

6 Abbreviations Term AED AML BSA EEG ITT MTOR NCBRF QOLCE QOLIE RCT SEGA SEN SPC SUDEP TSA TSC VNS Definition Antiepileptic drug Angiomyolipomas Body surface area Electroencephalogram Intention to treat Mammalian target of rapamycin Nisonger child behaviour rating form Quality of life in children with epilepsy Quality of life in epilepsy Randomised controlled trial Subependymal giant cell astrocytomas Subependymal nodule Summary of product characteristics Sudden unexplained death in epilepsy Tuberous Sclerosis Association Tuberous sclerosis complex Vagus nerve stimulation NHS URN 1700 / NICE ID001 Page 6 of 65

7 Introduction Disease background Tuberous sclerosis complex (TSC) is a condition that people are born with that often leads to non-cancerous growths developing in the brain, eye, heart, kidney, skin and lungs. TSC tumours of the brain can cause seizures. Seizures are one of the most common symptoms of TSC and occur in approximately 84% of people (Kingswood et al, TOSCA data, 2017). The rate of psychiatric problems in people with TSC is high. The four main disorders reported are depression, anxiety, attention deficit disorder and aggressive/disruptive behaviours (Muzykewicz, et al., 2007). Treatment with certain AEDs is known to increase the degree of cognitive and behavioural disorders in people with TSC-related seizures (French and Staley, 2012).Facial angiofibromas occur in about 75% of TSC patients with onset typically between ages 2 and 5 years (Northrup and Krueger, 2013). Angiofibromas can cause facial disfigurement which can lead to social isolation and depression (Crall, et al. 2016). Everolimus has also been reported to improve the appearance of skin lesions (facial angiofibromas) in these patients (Franz et al. 2016). In infants and children with TSC, seizures are closely related to development. Specifically, intellectual disability is associated with a history of infantile spasm (seizures which occur in infants) and refractory seizures (Wang and Fallah, 2014). The rate of learning disability in people with epilepsy population is high, especially in children who develop epilepsy early in life (NICE CG137). Early management of seizures is important in preventing and reducing the cognitive and neurological and psychiatric consequences from refractory seizures (Bombadieri, 2010). Long term intellectual development is thought to be improved if seizure treatment starts as soon as a child is diagnosed with epilepsy and when that treatment provides a prompt response (NICE CG137). Sudden unexpected death in epilepsy (SUDEP) is an important cause of mortality in people with TSC-related refractory epilepsy (Amin et al., 2016). Analysis of epilepsy studies have identified frequent convulsive seizures (3 or NHS URN 1700 / NICE ID001 Page 7 of 65

8 more in a year) as a major risk factor for SUDEP (Hesdorffer et al., 2011; Ryvlin et al., 2013) and several studies indicate that unsupervised night-time seizures significantly contribute to SUDEP risk (Lamberts et al., 2012). The aim of treatment, therefore, is to stop or reduce the number and frequency of seizures in patients with TSC as much as possible to limit the cognitive and neuropsychiatric consequences of refractory epilepsy and also ultimately to reduce the risk of SUDEP. Focus of review In line with the marketing authorisation, the focus of this review is on everolimus as an adjunctive (add-on) treatment for patients aged 2 years and older who have refractory focal onset seizures including those which evolve to bilateral tonic clonic seizures (formerly known as refractory partial-onset seizures with or without secondary generalisation) associated with TSC. A tonic clonic seizure (also called a convulsion) is a combination of tonic (meaning stiffening) and clonic (meaning rhythmical jerking) seizures. Focal onset seizures are those that start in an area on one side of the brain. When the seizure starts, the person may be aware or have some impaired awareness; if it spreads to both sides of the brain (that is, evolving to a bilateral tonic clonic seizure), the person would be unaware during the seizure. As the majority of TSC seizures have a focal origin, focal onset seizures will be used throughout this document to refer to focal onset seizures with or without evolution to bilateral tonic clonic seizures. Seizures can progress to become refractory, which is when the seizures no longer respond to anti-seizure treatment (also known as uncontrolled or intractable). In UK clinical practice, this means that 2 different anti-epileptic drugs (AEDs), given at therapeutic doses, have failed to reduce the frequency and severity of a person s seizures. People with refractory seizures associated with TSC currently have care tailored to their needs. The most common treatment used in UK practice is AEDs, however these are not disease modifying treatment option. Alternative symptom control treatment options for TSC-related refractory seizures include NHS URN 1700 / NICE ID001 Page 8 of 65

9 surgical resection (where it is possible to identify a dominant tumour that is causing the seizures), vagus nerve stimulation (VNS) or a ketogenic (low carbohydrate) diet. Everolimus (Votubia) is a drug that has a different mechanism of action to the currently available treatments. It targets the mammalian target of rapamycin (mtor) pathway, which is disrupted in TSC and causes a number of the symptoms of TSC. It is intended to be given as an adjunctive treatment, in addition to current standard of care. The Summary of product characteristics (SPC) states that treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs (see also Product Overview below). Epidemiology The estimated prevalence of the condition in the UK ranges between 8.8 per 100,000 (O'Callaghan et al., 1998) up to 10 in 100,000 (Committee for Medicinal Products for Human Use, European Medicines Agency, 2011). Based on this, it is estimated there are between 4,900 and 5,500 patients in England with TSC. However, this is likely to be an underestimation of the true prevalence, because prevalence is increasing with better identification of less severe cases. Approximately 84% of people with TSC have epilepsy and the majority of these people have focal onset seizures (equating to between 4,100 and 4,600 people). The proportion of patients with TSC-related refractory epilepsy varies depending on the evidence source between 36% (Kingswood et al., 2017) and 63% (Chu-Shore et al., 2010). Based on this, the number of people with TSCrelated refractory epilepsy in England is between 1,500 and 3,000 people, see Table 1. Table 1 Patient numbers Estimates Data source Number of NHS URN 1700 / NICE ID001 Page 9 of 65

10 people Population in England in mid-2016 Office for National Statistics 55,268, to 10 in 100,000 with TSC Epilepsy is in 84% of TSC patients Refractory to treatment - 36% to 63% Previous NHS England clinical policies on SEGA and AML, and company submission (Kingswood et al, TOSCA data, 2017) from company submission (Kingswood et al, TOSCA data, 2017) from company submission (Chu-Shore et al. 2010) 4,864 5,527 4,086 4,643 1,471 2,925 Product overview Mode of action The company state that everolimus works by inhibiting mtor, a protein that regulates multiple cellular functions. TSC is caused by mutations in the TSC1 or TSC2 genes, resulting in hyperactive signalling of the mtor pathway which can lead to increased cellular growth and proliferation, neuronal hyperexcitability, abnormalities in cortical architecture and network function and impaired synaptic plasticity. Regulatory status Everolimus (Votubia) received a marketing authorisation from the European Medicines Agency in January 2017 for the adjunctive treatment of patients aged 2 years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC). Dosing information Everolimus is available in the following formulations for the treatment of refractory seizures associated with TSC: Votubia 2 mg dispersible tablets Votubia 3 mg dispersible tablets Votubia 5 mg dispersible tablets NHS URN 1700 / NICE ID001 Page 10 of 65

11 Everolimus is given once daily. The following starting doses are recommended: Without co-administration of CYP3A4/PgP inducer 6mg/m2 for patients aged less than 6 years 5mg/m2 for patients aged 6 years or over With co-administration of CYP3A4/PgP inducer 9mg/m2 for patients aged less than 6 years 8mg/m2 for patients aged 6 years or over The SPC notes that treatment should be initiated by a physician experienced in the treatment of patients with TSC and therapeutic drug monitoring. It states that doses that will be tolerated and effective vary between patients. Dosing is individualised based on body surface area. Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs. Please see SPC for further details of the dosing recommendations. Treatment pathway and current practice The most common treatment used in UK clinical practice is AEDs. According to NICE clinical guideline 137, AED treatment strategy should be individualised according to the seizure type, epilepsy syndrome, comedication and co-morbidity, the child, young person or adult's lifestyle, and the preferences of the person and their family and/or carers as appropriate. In children, other treatment options for refractory seizures include a ketogenic diet, vagus nerve stimulation (VNS) or surgical resection. In adults, other treatments for refractory seizures include VNS and less commonly a ketogenic diet (due to the difficulty of remaining on the strict diet indefinitely) or surgical resection. A pathway of care for the treatment of refractory seizures associated with TSC in England is shown in Figure 1 below. NHS URN 1700 / NICE ID001 Page 11 of 65

12 Figure 1 Pathway of care for refractory seizures associated with TSC Innovation and unmet need Everolimus is understood to target the molecular pathology of TSC, and to modify the disease processes thought to be involved in the development of TSC symptoms. The company estimate that there is a large unmet need, as up to 37% of patients are refractory, and that there is a need for a well-tolerated diseasemodifying therapy that suppresses seizure symptoms and treats the disease. Equality No equalities issues relating to people with particular characteristics covered by the Equalities Act 2010 (including race, age, sex, disability, religion or belief, sexual orientation, gender reassignment, pregnancy, maternity, NHS URN 1700 / NICE ID001 Page 12 of 65

13 marriage and civil partnership) were identified during this review of the clinical evidence. Evidence review Identification of studies The review was done in line with NHS England s methods for carrying out clinical evidence reviews. A literature search was undertaken, which identified 329 references (see appendix 2 for search strategy). These references were screened using titles and abstracts and nine full text references were obtained and assessed for relevance. Full text inclusion and exclusion criteria were applied to the identified studies and six studies were included in the clinical evidence review (see appendix 3 for inclusion/exclusion criteria, flow of included studies, and a list of studies excluded at full text with reasons). The company submission identified five references to published studies in their submission. All of these studies were identified in the literature search, and as such no additional unique references were identified. The company also provided data for one unpublished study (Franz, in press), which was selected for inclusion. In summary seven studies met the inclusion/exclusion criteria and were subsequently included. The European public assessment report (EPAR) was also used to supplement the published data from the pivotal registration trial (French, 2016). Results Overview of included studies The highest grade (according to the National Service Framework Long-term Conditions (NSF-LTC) scoring system, see appendix 6) of available evidence comes from one phase III double-blinded, placebo-controlled RCT (EXIST-3) including 366 patients (French, 2016), together with a long-term uncontrolled NHS URN 1700 / NICE ID001 Page 13 of 65

14 extension study of the trial (Franz, in press). Five uncontrolled studies with smaller sample sizes (6-20 patients) also provide evidence. A summary of the characteristics of the included studies is shown in Table 2. More detailed evidence and results tables can be found in appendices 4 and 5. Table 2 Summary of included studies Study Population Intervention and comparator Follow-up French et al, (EXIST 3) Pivotal Phase III double-blind RCT Patients aged 2 65 years with a confirmed diagnosis of tuberous sclerosis complex and treatment resistant epilepsy 366 patients enrolled Across all treatment groups, the median age of patients was 10.1 years (range 2.2 to 56.3 years), 82% of patients were under 18 years old, 48% were female, and 65% of patients were Caucasian Low exposure - everolimus target trough of 3-7 ng/ml High exposure everolimus target trough of 9 15 ng/ml Placebo 12 weeks Franz et al, manuscript in preparation. Patients aged 2-65 years with a definitive diagnosis of TSC and refractory epilepsy Everolimus 3 15 ng/ml target trough range Up to 2 years Extension of Phase III RCT 361 patients included See French et al, 2016 below for details of population age and sex No comparator Kilincaslan et al, Case series (appears to be retrospective) Patients with TSC and refractory epilepsy 6 patients were included Patient age ranged from 7.5 to 23 years Everolimus 5 15 ng/ml target trough No comparator Median 17.5 months (range 7-26) Krueger et al, 2013 Phase I/II prospective uncontrolled study Patients aged 2 years or older with a confirmed diagnosis of tuberous sclerosis complex and treatment resistant epilepsy 20 patients were enrolled The median age of patients was 8 years (range 2 to 21 years), and 50% were female Everolimus 5 15 ng/ml target trough range No comparator 12 weeks Krueger et al, 2016 Long-term extension of phase I/II Patients aged 2 years or older with a confirmed diagnosis of tuberous sclerosis complex and treatment resistant epilepsy 18 patients entered the extension study Everolimus 5 15 ng/ml target trough range No comparator 48 months NHS URN 1700 / NICE ID001 Page 14 of 65

15 Study Population Intervention and comparator prospective uncontrolled study See Krueger et al, 2013 above for details of population age and sex Follow-up Samueli et al, 2016 Prospective uncontrolled before and after study Patients aged 18 years or younger with a confirmed diagnosis of tuberous sclerosis complex and treatment resistant TSC-associated epilepsy 15 patients were enrolled All of the enrolled patients were children with a median age of 6 years (range 1 to 18 years), and 40% were female Everolimus 5 15 ng/ml target trough range No comparator Median 22 months (range 6-50) Wiegand et al, 2013 Prospective uncontrolled before and after (compassionate use) study Patients with a confirmed diagnosis of tuberous sclerosis complex and treatment resistant epilepsy 7 patients were enrolled All of the enrolled patients were children with a median age of 5 years (range 2 to 12 years), and 57% were female Everolimus 5 10 ng/ml target trough range No comparator 9 months French (2016) was a double-blind, randomised, multi-centre trial evaluating the efficacy and safety of everolimus in patients age 2 (1 in Europe, however no one under age 2 was recruited to the study) to 65 who have TSC-related refractory seizures. At the time the patients joined the study, they were being treated with a stable regimen of 1 to 3 AEDs. To remain in the study, patients could not change the type or amount of AED medication they had been taking during the 8 week lead-in period before the study began (to ensure that the responses to treatment observed during the trial would mainly be due to the treatment effect of everolimus or placebo). The trial was conducted according to published protocols, reported clearly and included 366 patients. A majority (>80%) of patients included in the trial were aged under 18 years of age. Patients received a high exposure of everolimus, a low exposure of everolimus or placebo. For the first 6 weeks of the study, the dose of everolimus was slowly increased to the therapeutic dose (as is reflected in the marketing authorisation for everolimus). That therapeutic dose was then maintained for NHS URN 1700 / NICE ID001 Page 15 of 65

16 the following 12 weeks. The study inclusion criteria required that people have a clinically definitive diagnosis of TSC and refractory epilepsy (in the trial, the inclusion criterion relating to refractory epilepsy was a prior history of failure to control partial-onset seizures despite having been treated with two or more sequential regimens of single or combined antiepileptic drugs [See EXIST-3&rank=1 accessed October 2017]). For the purposes of the study, only patients who had more than 16 seizures (with no continuous 21-day seizures-free period) during the baseline period of the study were included. The patients recruited to the study had a baseline seizure rate of 34.5 to 42 seizures in a 28 day period and half of the included patients had been treated with 6 or more AEDs. In Franz (in press), the follow up study to French (2016), 361 of the patients from the EXIST-3 study were followed for up to 2 years. Patients who had originally received everolimus during the main trial remained on everolimus, and patients that originally received placebo were switched to everolimus. Patients were allowed to change AED or alter their AED dose during the follow up period. However, 47% of patients remained for a year or more on stable doses of the AEDs they were using throughout the study. Overview of key results Table 3 below provides a grade of evidence summary of the outcomes identified in the scope. The key effectiveness and safety outcomes are discussed below. Effectiveness The primary outcome in the French (2016) study was change from baseline in seizure frequency for each of the two everolimus dose groups (low and high exposure) compared with placebo during the 12-week maintenance period. Both response rate (that is, reduction in seizure frequency) and median percentage reduction in seizure frequency were assessed. Seizure frequency was defined as the ratio between the number of seizures and the number of days on which seizure information was known within the 12-week period. NHS URN 1700 / NICE ID001 Page 16 of 65

17 Evidence from this study suggests that everolimus as add-on treatment is effective at reducing the frequency of seizures compared to treatment with AEDs alone. In the trial, 28.2% [95% CI 20.3 to 37.3, p=0.0077] of patients receiving the lower dose of everolimus and 40.0% [31.5 to 49.0, p<0.0001] of patients receiving the higher dose of everolimus experienced at least a 50% reduction in the number of seizures, compared to 15.1% [95% CI 9.2 to 22.8] of patients receiving placebo. A reduction in seizure frequency of 25% or greater was seen in 52.1% (95% CI ) of patients in the low exposure everolimus group, and in 70.0% (95% CI ) of the patients the highexposure everolimus group, compared to 37.8% (95% CI ) in the placebo group. Across each treatment group, there was a 29.3% [95% CI 18.8 to 41.9, p=0.0028] and 39.6% [35.0 to 48.7, p<0.0001] median reduction in seizure frequency at 12 weeks in the lower dose and higher dose of everolimus compared with baseline, and a 14.9% [95% CI 0.1 to 21.7] median reduction in seizure frequency compared with baseline in the group receiving placebo. Evidence from the phase III extension study (Franz, in press) which studied 361 patients up to 2 years indicates that the benefit of treatment with everolimus increases over time. In the study, the percentage of people with a reduction in seizure frequency of at least 50% was 31% at week 18, 46.6% at 1 year and 57.7% at 2 years of treatment with everolimus (these preceding data will be included in Franz et al., but have already been presented in a poster and therefore are not considered academic-in-confidence). Franz et al. has been taken into account by the policy working group as a confidential draft of the article which was provided by the company. This will be published in the near future and will be available at the time a commissioning policy is considered for routine commissioning. Behaviour and quality of life The French study investigators had intended to report the effect of everolimus on patient behaviour using the Vineland Adaptive Behavior Scale Survey. However, investigators were unable to perform the survey at baseline for many of the patients due to the severity of the patient s disability. NHS URN 1700 / NICE ID001 Page 17 of 65

18 Evidence from the other studies included in the clinical evidence review for everolimus, suggested that behaviour improved during everolimus treatment. The Krueger 2013 study was a single arm study which included 20 patients which assessed the benefit of everolimus on seizure control in patients with TSC-related refractory epilepsy. The study showed there was a statistically significant reduction in negative domain behaviour (which include conduct problems, anxiety, hyperactivity, self-injury, self-isolation and oversensitivity). There was also an improvement in positive domain behaviour (which includes compliance and social adaptiveness) although this was not statistically significant. There was a statistically significant increase in the overall QOLCE score (+1.0, p<0.001), which was driven by changes in attention, behaviour, social interaction, other cognitive, stigma, physical restrictions and social activity domains. It should be noted that patients in the Krueger 2013 study had to their current stable dose of AEDs throughout the study. In the 48 month follow up study (Krueger, 2016), quality of life measured by the QOLCE composite score improved an average of 14% (43.7 ± 13.4 at baseline compared to 52.0 ± 17.8 after 48 months). There were positive changes in stigma, self-rated quality of life, attention/concentration, anxiety, language, and general health but the results did not reach statistical significance due to individual variation and cohort size. Trends in behaviour improvement in both positive and negative domains were also observed after 48 months of treatment, but similarly did not reach statistical significance. Patients in the Krueger 2016 extension study were allowed changes to their AED medication. For example, one patient stopped AED treatment during the extension phase of the Krueger study and maintained seizure control with everolimus alone. However, the overall number of AEDs used by patients during the 48 months remained unchanged (median 5 2, range 0 4). Safety and tolerability Evidence from the phase III extension study (Franz, in press) which studied 361 patients up to 2 years indicated what the most frequent treatment-related adverse effects were. The safety and tolerability data from Franz et al. has been taken into account by the policy working group as a confidential draft of NHS URN 1700 / NICE ID001 Page 18 of 65

19 the article which was provided by the company. This will be published in the near future and will be available at the time a commissioning policy is considered for routine commissioning. Evidence gaps The evidence base available for everolimus provides a comparison of everolimus in combination with AEDs against a comparison/baseline of AED therapy. As everolimus was evaluated as an add-on to current treatment, it is not intended to replace current therapies. Therefore comparative evidence does not exist. The trial population included the population covered by the marketing authorisation with respect to seizure burden and prior AED use at baseline, however, the median values for seizure burden and AED use at baseline were higher than would be expected in NHS clinical practice (median seizure frequency per 28 days at baseline was 37 8 seizures [1 to 874] and just under half of the population had tried 6 or more AEDs at baseline). There is limited long term evidence (2 years or more) for everolimus use in people with TSC related refractory focal onset seizures. Therefore, consideration should be given to regular monitoring of patients receiving everolimus beyond 2 years for TSC-related refractory focal onset seizures in order to promptly identify any adverse effects of treatment with everolimus. Key ongoing studies The following study is ongoing until 2028 to collect long-term safety data: Trial NCT ; CRAD001M2X02B: Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment. Currently recruiting. Estimated completion date: January NHS URN 1700 / NICE ID001 Page 19 of 65

20 Table 3 Grade of evidence for key outcomes Outcome measure Study Critical appraisal score Applicability to decision problem Grade of evidence Interpretation of evidence Response rate of 50% reduction in seizures Franz, in press French, 2016 Krueger, /10 Directly 9/10 Directly 4/10 Directly A Response rate of 50% reduction in seizures is the percentage of patients who had at least half the number of seizures they were having at the start of the study. The largest study (French, 2016) with 366 patients reported a response rate of 50% reduction in seizures in 40% of patients treated with high dose everolimus and 28% of patients treated with low dose everolimus, compared to 15% of patients receiving AEDs only (the placebo group) after 12 weeks follow-up. Krueger, 2013 Samueli, 2016 Wiegand, /10 Directly 3/10 Directly 3/10 Directly The longest-term evidence from the largest extension trial available (Franz et al., in press) included 361 patients from the original trial who were all given everolimus. The trial reported a 50% reduction in seizure frequency in 31% of patients at week 18, 46.6% at 1 year, and 57.7% at 2 years (these preceding data will be included in Franz et al., but have already been presented in a poster and therefore are not considered academic-in-confidence). The unpublished results from Franz et al. have been taken into account by the policy working group based on a confidential draft of the article which was provided by the company. This will be published in the near future and will be available at the time a commissioning policy is considered for routine commissioning. The results from French (2016) and Franz (in press) suggest that 30% of patients treated with everolimus can expect a 50% reduction in seizure frequency from baseline at week 12 after starting treatment. The results also suggest that the benefit of treatment can increase over time. The NHS URN 1700 / NICE ID001 Page 20 of 65

21 Outcome measure Study Critical appraisal score Applicability to decision problem Grade of evidence Interpretation of evidence greatest benefit was reported in patients initially randomised to high dose everolimus.). It should be noted that the patients included in the study had a higher seizure frequency rate than expected in patients in England and just under half had tried 6 or more AEDs previously. Median % reduction in seizures Franz, in press French, 2016 Kilincaslan, 2017 Krueger, 2016 Krueger, /10 Directly 9/10 Directly 2/10 Directly 4/10 Directly 6/10 Directly A Median percentage reduction in seizures is a measure of the reduction in seizure frequency relative to baseline seizure frequency at the start of the study. The largest study (French, 2016) with 366 patients reported a median 40% and 29% reduction in seizures in the high and low dose everolimus groups, respectively at 12 weeks follow-up. In the AED only (placebo) group, there was a median 15% reduction in seizures in patients. The longest-term evidence from the largest extension trial (Franz, in press) reported a median 31.7% reduction in seizure frequency at week 18, a median 46.7% reduction at 1 year, and a median 56.9% reduction at 2 years. The results from the French (2016) and Franz (in press) suggest that patients treated with everolimus can expect a 29% reduction in seizure frequency at week 12. The results also suggest that the benefit of treatment can increase over time. The greatest benefit was reported in patients initially randomised to high dose everolimus. It should be noted that the patients included in the study had a higher seizure frequency rate than expected in patients in England and just NHS URN 1700 / NICE ID001 Page 21 of 65

22 Outcome measure Study Critical appraisal score Applicability to decision problem Grade of evidence Interpretation of evidence under half had tried 6 or more AEDs previously. Median number of additional seizure free days per 28 days Franz, in press French, 2016 Samueli, /10 Directly 9/10 Directly 3/10 Directly A The median number of additional seizure free days per 28 days a measure of the additional number of days without any countable seizures in a 28 day period. The unpublished results from Franz et al. have been taken into account by the policy working group based on a confidential draft of the article which was provided by the company. This will be published in the near future and will be available at the time a commissioning policy is considered for routine commissioning. It should be noted that the patients included in the study had a higher seizure frequency rate compared to the expected seizure frequency rate for patients with refractory TSC-related seizures in England and just under half had tried 6 or more AEDs previously. Patients remaining seizure free Franz, in press French, 2016 Krueger, /10 Directly 9/10 Directly 4/10 Directly Krueger, 6/10 Directly A Patients remaining seizure free is a measure of the number of patients in the trial who had no countable seizures during the trial. The largest study (French, 2016) with 366 patients reported that 6 out of 117 (5%) patients in the low dose everolimus group and 5 out of 130 (4%) patients in the high dose everolimus group had no countable seizures compared to 1 out of 119 (0.8%) patients in the AEDs only (placebo) group at 12 weeks follow up. The longest-term evidence from the largest extension trial (Franz, in press) included 361 patients from the original trial who were all given NHS URN 1700 / NICE ID001 Page 22 of 65

23 Outcome measure Study Critical appraisal score Applicability to decision problem Grade of evidence Interpretation of evidence 2013 Samueli, /10 Directly everolimus. The unpublished results from Franz et al. have been taken into account by the policy working group based on a confidential draft of the article which was provided by the company. This will be published in the near future and will be available at the time a commissioning policy is considered for routine commissioning. Wiegand, /10 Directly The results from the French and Franz studies suggest that 4 out of 100 patients treated with everolimus can expect seizure freedom at week 18 of everolimus treatment and that the benefit of treatment with everolimus can increase over time. The greatest benefit was reported in patients who were remained in the study, leading the study authors to report that the benefit of everolimus is dependent on length of treatment (longer treatment durations corresponded with better outcomes). It should be noted that the patients included in the study had a higher seizure frequency rate compared to the expected seizure frequency rate for patients with refractory TSC-related seizures in England and just under half had tried 6 or more AEDs previously. Quality of life French, 2016 Krueger, 2016 Krueger, /10 Directly 4/10 Directly 6/10 Directly B Quality of life is a measure of a patient s quality of life. It is usually based on a questionnaire which is completed by the patient or parent/carer. Like other outcomes, it is measured at baseline and then again during and at the end of the study. The largest study (French, 2016) with 366 patients reported that there was no difference in quality of life measures. A study with 20 patients (Krueger, 2013) reported a benefit in Quality of Life Childhood Epilepsy (QOLCE) questionnaire, which was driven by improvements in attention, behaviour, and social interaction domains. No NHS URN 1700 / NICE ID001 Page 23 of 65

24 Outcome measure Study Critical appraisal score Applicability to decision problem Grade of evidence Interpretation of evidence improvement in quality of life was reported was during the extension study (Krueger, 2016). The results from the studies suggest that patients treated with everolimus may not see a consistent benefit in quality of life measures. The results from Krueger should be interpreted with caution as they are based on a small single arm study. It means that it did not randomise patients or compare the treatment with any other standard treatment. It should also be noted that the French (2016) study had difficulties in collecting the quality of life data, due to many of the patients enrolled having cognitive impairments which prevented the measurement of quality of life using the questionnaires available. Changes to concomita nt AED medicatio n Franz, in press Samueli, 2016 Wiegand, /10 Directly 3/10 Directly 3/10 Directly B Changes to concomitant AED medication means a measurement of changes to the amount and type of AEDs taken by patients in the studies in addition to everolimus or placebo. The largest study with 361 patients was the extension of the main trial (Franz, in press). In the extension study, patients together with their treating clinician were allowed to make changes to their AED medication. The unpublished results from Franz et al. have been taken into account by the policy working group based on a confidential draft of the article which was provided by the company. This will be published in the near future and will be available at the time a commissioning policy is considered for routine commissioning. The results from the extension study suggest patients being treated with everolimus can expect no change in their AED usage over time. This also suggests that there is less of a need to try a different AED medication as NHS URN 1700 / NICE ID001 Page 24 of 65

25 Outcome measure Study Critical appraisal score Applicability to decision problem Grade of evidence Interpretation of evidence efficacy is maintained with the current AED with everolimus as add on treatment. It should be noted that the just under half of patients in the Franz study had tried 6 or more AEDs previously. Patient behaviour Kilincaslan, 2017 Krueger, 2016 Krueger, /10 Directly 4/10 Directly 6/10 Directly B Patient behaviour means changes in patient behaviour over time including changes positive (or social) and negative (or antisocial) behaviours. The largest study (Krueger, 2013) with 20 patients reported mixed results indicating an improvement (reduction) in negative behaviour, but no significant improvement in positive behaviours. The results of the extension study (Krueger, 2016) suggested no difference in patient behaviour over 48 months. The results from the studies suggest that patients treated with everolimus may not see a clear improvement in behaviour. The results from Krueger should be interpreted with caution as they are based on a small single arm study. It means that it did not randomise patients or compare the treatment with any other standard treatment. It should also be noted that the French (2016) study had intended on collecting the patient behaviour data, but was unable to do so due to many of the patients enrolled having cognitive impairments which prevented the measurement of patient behaviour using the questionnaires available. Safety Franz, in 7/10 Directly A All Adverse events NHS URN 1700 / NICE ID001 Page 25 of 65

26 Outcome measure Study Critical appraisal score Applicability to decision problem Grade of evidence Interpretation of evidence press French, /10 Directly The largest study (Franz, in press) studied 361 patients up to 2 years. The unpublished results from Franz et al. have been taken into account by the policy working group based on a confidential draft of the article which was provided by the company. This will be published in the near future and will be available at the time a commissioning policy is considered for routine commissioning. Kilincaslan, /10 Directly Krueger, 2016 Krueger, /10 Directly 6/10 Directly The results from the studies suggest that most patients treated with everolimus may experience an adverse event, but that adverse events did not increase over time. Samueli, /10 Directly Wiegand, /10 Directly Discontinu ation rates Franz, in press 7/10 Directly B Discontinuation rates means the number of patients who stopped using everolimus for any reason during the trial. Krueger, 2016 Samueli, /10 Directly 3/10 Directly The largest study (Franz, in press) studied 361 patients up to 2 years. The unpublished results from Franz et al. have been taken into account by the policy working group based on a confidential draft of the article which was provided by the company. This will be published in the near future and will be available at the time a commissioning policy is NHS URN 1700 / NICE ID001 Page 26 of 65

27 Outcome measure Study Critical appraisal score Applicability to decision problem Grade of evidence Interpretation of evidence Wiegand, /10 Directly considered for routine commissioning. The results from the studies suggest that some patients treated with everolimus may stop taking it due to side effects or because it is no longer reducing the frequency or severity of their seizures. The results should be interpreted with caution as this was a trial setting, and the number of patients stopping treatment clinical practice could vary. NHS URN 1700 / NICE ID001 Page 27 of 65

28 Relevance to NICE guidelines and NHS England policies There are no specific NICE guidelines on this topic. The following NICE clinical guideline makes reference to TSC-associated seizures: Epilepsies: diagnosis and management (2012 updated 2016) NICE guideline CG137 The following NHS England policies are in TSC but in different indications: Clinical Commissioning Policy Statement: Everolimus (Votubia ) for treatment of angiomyolipomas associated with tuberous sclerosis. June NHS England Reference B14X09. Clinical Commissioning Policy: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex December NHS England Reference 16066/P. NHS URN 1700 / NICE ID001 Page 28 of 65

29 References Included studies Amin, S., Lux, A., Calder, N., Laugharne, M., Osborne, J. and O Callaghan, F. (2016) Causes of mortality in individuals with tuberous sclerosis complex. Developmental Medicine & Child Neurology, 59(6) pp Bombardieri, R., Pinci, M., Moavero, R., Cerminara, C. and Curatolo, P. (2010). Early control of seizures improves long-term outcome in children with tuberous sclerosis complex. European Journal of Paediatric Neurology, 14(2): pp Chu-Shore, C.J. Major, P., Camposano, S., Muzykewicz, D. and Thiele, E.A., (2010). The natural history of epilepsy in tuberous sclerosis complex. Epilepsia, 51(7) pp ClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US) 2017 August 24. Identifier NCT Novartis: A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (EXIST-3). Available from Crall, C., Valle, M., Kapur, K., Dies K.A., Liang, M.G., Sahin, M. and Huang, J.T. (2016) Effect of Angiofibromas on Quality of Life and Access to Care in Tuberous Sclerosis Patients and Their Caregivers. Pediatric Dermatology, 33(5), pp European Medicines Agency (2017) EMA/ H/C/ II/0044 Votubia: EPAR Product Information: Annex I Summary of product characteristics. Product_Information/human/002311/WC pdf, October Fisher, R.S. Cross, J.H., D Souza, C., French, J., Haut, S.R., Higurashi, N., Hirsch, E., Jansen, F.E., Lagae, L., Moshe, S.L. Peltola, J., Roulet Perez, E., Scheffer, I.E., Schulze-Bonhage, A., Somerville, E., Sperling, M., Yacubian, E.M. and Zuberi, S.M. (2017) Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia, 58(4), pp Franz, D.N., Belousova, E., Sparagana, S., Martina Bebin, E., Frost, M.D., Kupermen, R., Witt, O., Kohrman, M.H., Flamini, J.R., Wu, J.Y., Curatolo, P. de Vries, P.J., Berkowitz, N., Niolat, J., and Jóźwiak, S. (2016) Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study. PLoS ONE 11(6) October French, J., Lawson, J., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P., Dlugos, D., Berkowitz, N., Voi, M., Peyrard, S., Pelov, D. and Franz, D. (2016). Adjunctive everolimus therapy for treatment- NHS URN 1700 / NICE ID001 Page 29 of 65

30 resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. The Lancet, 388(10056), pp French, J. and Staley, B.A. (2012) AED Treatment Through Different Ages: As Our Brains Change, Should Our Drug Choices Also? Epilepsy Currents, 12 (Suppl. 3); pp Kilincaslan, A., Kok, B.E., Tekturk, P., Yalcinkaya, C., Ozkara C., and Yapici Z. (2017) Beneficial Effects of Everolimus on Autism and Attention- Deficit/Hyperactivity Disorder Symptoms in a Group of Patients with Tuberous Sclerosis Complex. Journal of child and adolescent psychopharmacology 27, Krueger, D.A., Wilfong, A.A., Holland-Bouley, K., Anderson, A.E., Agricola, K., Tudor, C., Mays, M., Lopez, C.M., Kim, M-O., and Franz, D.N. (2013) Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Annals of neurology 74, Krueger, D.A., Wilfong, A.A, Mays. M., Talley, C.M., Agricola, K., Tudor, C., Capal, J., Holland-Bouley. K., and Franz, D.N. (2016) Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology 87, Lamberts, R.J., Thijs, R.D., Laffan, A., Langan, Y. and Sander, J.W. (2012) Sudden unexpected death in epilepsy: people with nocturnal seizures may be at highest risk. Epilepsia, 53(2): pp Muzykewicz, D.A., Newberry, P., Danforth. N., Halpern, E.F. and Thiele, E.A. (2007) Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy & Behavior, 11(4), pp National Institute for Health and Care Excellence. (2016). Epilepsies: diagnosis and management. NICE guideline (CG137) United Kingdom. Northrup, H. and Krueger, D.A. (2013) Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurology, 49: pp O'Callaghan, F.J.K., Shiell, A.W., Osborne, J.P. and Martyn, C.N. (2008). Prevalence of tuberous sclerosis estimated by capture-recapture analysis. The Lancet, 351: p1490. Ryvlin, P., Nashef, L., Lhatoo, S.D., Bateman, L.M., Bird, J., Bleasel, A., Boon, P., Crespel, A., Dworetzky, B.A., Høgenhaven, H., Lerche, H., Maillard, L., Malter, M.P., Marchal, C., Murthy, J.M., Nitsche, M., Pataraia, E., Rabben, T., Rheims, S., Sadzot, B., Schulze-Bonhage, A., Seyal, M., So, E.L., Spitz, M., Szucs, A., Tan, M., Tao, J.X., and Tomson, T. (2013). Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study. Lancet Neurology, 12(10), pp NHS URN 1700 / NICE ID001 Page 30 of 65

Clinical Commissioning Policy Proposition: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex

Clinical Commissioning Policy Proposition: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex Clinical Commissioning Policy Proposition: Everolimus for subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex Reference: NHS England E09X04/01 Information Reader Box (IRB)

More information

Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up

Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up Dermatol Ther (Heidelb) (2017) 7:175 179 DOI 10.1007/s13555-017-0174-5 CASE REPORT Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term

More information

Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension)

Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension) Pharmacy Medical Necessity Guidelines: Afinitor (everolimus) & Afinitor Disperz (everolimus tablets for oral suspension) Effective: June 1, 2017 Prior Authorization Required Type of Review Care Management

More information

eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd

eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd 8 October 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

More information

All visits for patients with diagnosis of epilepsy. Denominator Statement Denominator Exceptions

All visits for patients with diagnosis of epilepsy. Denominator Statement Denominator Exceptions Measure 2: Etiology, Seizure Type, or Epilepsy Syndrome Measure Description Percent of all visits for patients with a diagnosis of with seizure type and etiology or syndrome documented OR testing* ordered

More information

Denominator Exceptions

Denominator Exceptions MEASURE #5: Screening for Psychiatric or Behavioral Health Disorders Measure Description Percent of all visits for patients with a diagnosis of epilepsy where the patient was screened for psychiatric or

More information

Surveillance report Published: 13 April 2017 nice.org.uk. NICE All rights reserved.

Surveillance report Published: 13 April 2017 nice.org.uk. NICE All rights reserved. Surveillance report 2017 Antisocial behaviour and conduct disorders in children and young people: recognition and management (2013) NICE guideline CG158 Surveillance report Published: 13 April 2017 nice.org.uk

More information

Practical Considerations for the Identification, Diagnosis, and Management of Patients With Tuberous Sclerosis Complex Presentation 1

Practical Considerations for the Identification, Diagnosis, and Management of Patients With Tuberous Sclerosis Complex Presentation 1 Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants

More information

The natural history of epilepsy in tuberous sclerosis complex

The natural history of epilepsy in tuberous sclerosis complex The natural history of epilepsy in tuberous sclerosis complex The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters. Citation Published

More information

CONVULSIONS - AFEBRILE

CONVULSIONS - AFEBRILE Incidence All Children require Management Recurrence Risk Indications for starting therapy Starting Anticonvulsant medication Criteria for Referral to Paediatric Neurology Useful links References Appendix

More information

TRANSPARENCY COMMITTEE OPINION. 19 July 2006

TRANSPARENCY COMMITTEE OPINION. 19 July 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated

More information

Ernie Somerville Prince of Wales Hospital EPILEPSY

Ernie Somerville Prince of Wales Hospital EPILEPSY Ernie Somerville Prince of Wales Hospital EPILEPSY Overview Classification New and old anti-epileptic drugs (AEDs) Neuropsychiatric side-effects Limbic encephalitis Non-drug therapies Therapeutic wishlist

More information

Clinical Commissioning Policy Proposition: Robotic assisted lung resection for primary lung cancer

Clinical Commissioning Policy Proposition: Robotic assisted lung resection for primary lung cancer Clinical Commissioning Policy Proposition: Robotic assisted lung resection for primary lung cancer Reference: NHS England B10X03/01 Information Reader Box (IRB) to be inserted on inside front cover for

More information

Clinical Commissioning Policy Proposition:

Clinical Commissioning Policy Proposition: Clinical Commissioning Policy Proposition: Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), vasculitis of the peripheral nervous system

More information

Common Drug Review Clinical Review Report

Common Drug Review Clinical Review Report Common Drug Review Clinical Review Report September 2017 Drug everolimus (Afinitor) (oral tablets) Indication For the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with

More information

Seizure remission in adults with long-standing intractable epilepsy: An extended follow-up

Seizure remission in adults with long-standing intractable epilepsy: An extended follow-up Epilepsy Research (2010) xxx, xxx xxx journal homepage: www.elsevier.com/locate/epilepsyres Seizure remission in adults with long-standing intractable epilepsy: An extended follow-up Hyunmi Choi a,, Gary

More information

The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care

The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care Issued: January 2012 guidance.nice.org.uk/cg137 NHS Evidence has accredited the process

More information

Child Neurology. The Plural. of anecdote. is not evidence. University of Texas Health Science Center at San Antonio

Child Neurology. The Plural. of anecdote. is not evidence. University of Texas Health Science Center at San Antonio Child Neurology Management of Seizure Disorders The stated goal of advocacy groups for patients with seizures, is to have the patient seizure free. S W Atkinson, MD Management of When to pharmacologically

More information

Tuberous Sclerosis Complex: Clinical overview

Tuberous Sclerosis Complex: Clinical overview Tuberous Sclerosis Complex: Clinical overview Elizabeth A. Thiele, MD, PhD Director, Carol and James Herscot Center for Tuberous Sclerosis Complex Director, MGH Pediatric Epilepsy Program Professor of

More information

Technology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta489

Technology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta489 Vismodegib for treating basal cell carcinoma Technology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta489 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Clinical Commissioning Policy Proposition: Selexipag in the treatment of Pulmonary Arterial Hypertension

Clinical Commissioning Policy Proposition: Selexipag in the treatment of Pulmonary Arterial Hypertension Clinical Commissioning Policy Proposition: Selexipag in the treatment of Pulmonary Arterial Hypertension Reference: NHS England A11X04/01 Information Reader Box (IRB) to be inserted on inside front cover

More information

EPILEPSY. New Ideas about an Old Disease. Gregory D. Cascino, MD

EPILEPSY. New Ideas about an Old Disease. Gregory D. Cascino, MD EPILEPSY New Ideas about an Old Disease Gregory D. Cascino, MD Disclosure Research-Educational Grants Neuro Pace, Inc. American Epilepsy Society American Academy of Neurology Neurology (Associate Editor)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/590275/2014 European Medicines Agency decision P/0275/2014 of 28 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lacosamide (Vimpat), (EMEA-000402-PIP02-11-M01)

More information

The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care

The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care Issued: January 2012 last modified: January 2015 guidance.nice.org.uk/cg137 NICE has

More information

SUDEP: Sudden Unexpected Death in Epilepsy on Placebo?

SUDEP: Sudden Unexpected Death in Epilepsy on Placebo? Current Literature In Clinical Science SUDEP: Sudden Unexpected Death in Epilepsy on Placebo? Risk of Sudden Unexpected Death in Epilepsy in Patients Given Adjunctive Antiepileptic Treatment for Refractory

More information

Placename CCG. Policies for the Commissioning of Healthcare

Placename CCG. Policies for the Commissioning of Healthcare Placename CCG Policies for the Commissioning of Healthcare Policy for the funding of insulin pumps and continuous glucose monitoring devices for patients with diabetes 1 Introduction 1.1 This document

More information

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442 Ixekizumab for treating moderate to severe ere plaque psoriasis Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta442 NICE 2017. All rights reserved. Subject to Notice of rights

More information

amifampridine 10mg tablet, as phosphate (Firdapse ) BioMarin UK Ltd

amifampridine 10mg tablet, as phosphate (Firdapse ) BioMarin UK Ltd amifampridine 10mg tablet, as phosphate (Firdapse ) BioMarin UK Ltd SMC No.(660/10) 06 July 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE The management of faecal incontinence in adults 1.1 Short title Faecal incontinence 2 Background (a) (b) (c) The National Institute

More information

Opinion 24 July 2013

Opinion 24 July 2013 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008

The legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release

More information

Technology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416

Technology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation- positive non-small-cell lung cancer Technology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416 NICE

More information

What the IOM Report Means for Basic and Clinical Research December 1, 2012

What the IOM Report Means for Basic and Clinical Research December 1, 2012 What the IOM Report Means for Basic and Clinical Research December 1, 2012 Story C. Landis, PhD Director, National Institute of Neurological Disorders and Stroke American Epilepsy Society Annual Meeting

More information

From Diagnosis to Intervention: ASD & Seizures-Epilepsy Indications for EEG and MRI. Reet Sidhu, MD Gregory Barnes, MD Nancy Minshew, MD

From Diagnosis to Intervention: ASD & Seizures-Epilepsy Indications for EEG and MRI. Reet Sidhu, MD Gregory Barnes, MD Nancy Minshew, MD From Diagnosis to Intervention: ASD & Seizures-Epilepsy Indications for EEG and MRI Reet Sidhu, MD Gregory Barnes, MD Nancy Minshew, MD Overview Autism Spectrum Disorders (ASD) and the role of the Neurologist

More information

Technology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487

Technology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487 Venetoclax for treating chronic lymphocytic leukaemia Technology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Insert heading depending. cover options once. other cover options once you have chosen one. 20pt. Ref: N-SC/031

Insert heading depending. cover options once. other cover options once you have chosen one. 20pt. Ref: N-SC/031 Insert heading depending Insert Interim Insert heading Clinical Commissioning depending on line on on Policy: line length; length; please please delete delete on line line Spinal length; Surgery please

More information

Specialised Services Commissioning Policy. CP29: Bariatric Surgery

Specialised Services Commissioning Policy. CP29: Bariatric Surgery Specialised Services Commissioning Policy CP29: Bariatric Surgery Document Author: Specialist Planner, Cardiothoracic Executive Lead: Director of Planning Approved by: Management Group Issue Date: 12 June

More information

Clinical guideline Published: 11 January 2012 nice.org.uk/guidance/cg137

Clinical guideline Published: 11 January 2012 nice.org.uk/guidance/cg137 Epilepsies: diagnosis and management Clinical guideline Published: 11 January 2012 nice.org.uk/guidance/cg137 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

RESEARCH ARTICLE EPILEPSY IN CHILDREN WITH CEREBRAL PALSY

RESEARCH ARTICLE EPILEPSY IN CHILDREN WITH CEREBRAL PALSY RESEARCH ARTICLE EPILEPSY IN CHILDREN WITH CEREBRAL PALSY S.Pour Ahmadi MD, M.Jafarzadeh MD, M. Abbas MD, J.Akhondian MD. Assistant Professor of Pediatrics, Mashad University of Medical Sciences. Associate

More information

Document Title Pharmacological Management of Generalised Anxiety Disorder

Document Title Pharmacological Management of Generalised Anxiety Disorder Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)

More information

Epilepsy is Seizure Recognition & Response. Epilepsy Facts. Possible Causes of Epilepsy. What happens to the brain during a seizure?

Epilepsy is Seizure Recognition & Response. Epilepsy Facts. Possible Causes of Epilepsy. What happens to the brain during a seizure? Epilepsy is Seizure Recognition & Response NOT contagious NOT a mental illness NOT a mental impairment NOT a single disease Epilepsy is A neurological disorder of the brain characterized by the tendency

More information

Specialised Services Policy:

Specialised Services Policy: Specialised Services Policy: CP35 Cochlear Implants Document Author: Specialised Planner for Women & Children s Services Executive Lead: Director of Planning Approved by: Executive Board Issue Date: 05

More information

Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493

Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 Cladribine tablets for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 NICE 2018. All rights reserved. Subject to Notice

More information

Technology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411

Technology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411 Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer Technology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411 NICE 2017. All rights reserved.

More information

pat hways Medtech innovation briefing Published: 29 November 2016 nice.org.uk/guidance/mib87

pat hways Medtech innovation briefing Published: 29 November 2016 nice.org.uk/guidance/mib87 pat hways CytoSorb therapy for sepsis Medtech innovation briefing Published: 29 November 2016 nice.org.uk/guidance/mib87 Summary The technology described in this briefing is CytoSorb therapy. It is an

More information

Seizures explained. What is a seizure? Triggers for seizures

Seizures explained. What is a seizure? Triggers for seizures Seizures explained What is a seizure? A seizure is a sign of a temporary disruption in the brain s electrical activity. Billions of brain cells pass messages to each other and these affect what we say

More information

New Drug Evaluation: brivaracetam [tablet and solution, oral; solution, intravenous]

New Drug Evaluation: brivaracetam [tablet and solution, oral; solution, intravenous] Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

13th ECE - Programme at a Glance

13th ECE - Programme at a Glance Neurobiology 14.30-16.00 Sunday 26th August Neonatal Session (5) seizure 14.30-16.00 guidelines 14.00-16.30 Set Up ~ Posters on Display all day ~ Authors present (14.00-14.40) Take Dow Monday 27th August

More information

School Hearing Screening Policy

School Hearing Screening Policy School Hearing Screening Policy V2.1 1st August 2017 Page 1 of 13 Table of Contents 1. Introduction... 3 2. Purpose of this Policy... 3 3. Scope... 3 4. Definitions / Glossary... 3 5. Ownership and Responsibilities...

More information

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380

Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380 Panobinostat for treating multiple myeloma after at least 2 previous treatments Technology appraisal guidance Published: 27 January 2016 nice.org.uk/guidance/ta380 NICE 2017. All rights reserved. Subject

More information

NICE Clinical Guidelines recommending Family and Couple Therapy

NICE Clinical Guidelines recommending Family and Couple Therapy Association for Family Therapy and Systemic Practice NICE Clinical Guidelines recommending Family and Couple Therapy August 2016 Compiled by: Dr Lucy Davis (Chartered and Clinical Psychologist/Trainee

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Shared Care Guideline for the treatment of Tourette s Syndrome and other tic disorders in children and adolescents. Scope: Version: Pennine Care NHS Foundation Trust NHS Bury NHS

More information

New antiepileptic drugs

New antiepileptic drugs Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont

More information

Attention deficit hyperactivity disorder

Attention deficit hyperactivity disorder Attention deficit hyperactivity disorder Diagnosis and management of ADHD in children, young people and adults Issued: September 2008 last modified: March 2013 NICE clinical guideline 72 guidance.nice.org.uk/cg72

More information

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta465

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta465 Olaratumab atumab in combination with doxorubicin orubicin for treating advanced soft tissue sarcoma Technology appraisal guidance Published: 9 August 17 nice.org.uk/guidance/ta465 NICE 17. All rights

More information

Shared Care Guidance. Vigabatrin

Shared Care Guidance. Vigabatrin North of Tyne Area Prescribing Committee Shared Care Guidance Vigabatrin July 2014 (Review date July 2016) This guidance has been prepared and approved for use in Newcastle, North Tyneside and Northumberland.

More information

Update in Clinical Guidelines in Epilepsy

Update in Clinical Guidelines in Epilepsy Why We Need Clinical Guidelines? Clinician needs advice! Update in Clinical Guidelines in Epilepsy Charcrin Nabangchang, M.D. Phramongkutklao College of Medicine Tiamkao S, Neurology Asia2013 Why We Need

More information

21 ST CENTURY TECHNOLOGY IN PEDIATRIC NEUROLOGIC DISORDERS PEDIATRIC NEUROLOGIC DISORDERS YOUR LEARNING EXPERIENCE LEARNING OBJECTIVES

21 ST CENTURY TECHNOLOGY IN PEDIATRIC NEUROLOGIC DISORDERS PEDIATRIC NEUROLOGIC DISORDERS YOUR LEARNING EXPERIENCE LEARNING OBJECTIVES 21 ST CENTURY TECHNOLOGY IN PEDIATRIC NEUROLOGIC DISORDERS Saturday, April 30, 2016 11:00 am David J. Siegler, M.D. Board Certified American Board of Psychiatry and Neurology National Board of Physicians

More information

BIBLIOGRAPHIC REFERENCE TABLE FOR SODIUM VALPROATE IN CHILDHOOD EPILEPSY

BIBLIOGRAPHIC REFERENCE TABLE FOR SODIUM VALPROATE IN CHILDHOOD EPILEPSY BIBLIOGRAPHIC REFERENCE TABLE FOR SODIUM VALPROATE IN CHILDHOOD EPILEPSY Bibliographic Marson AG et al. for (Review). The Cochrane 2000 De Silva M et al. Romised or for childhood. Lancet, 1996; 347: 709-713

More information

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

The Outcome of Children with Intractable Seizures: A 3- to 6-Year Follow-up of 67 Children Who Remained on the Ketogenic Diet Less Than One Year

The Outcome of Children with Intractable Seizures: A 3- to 6-Year Follow-up of 67 Children Who Remained on the Ketogenic Diet Less Than One Year Epilepsia, 47(2):425 430, 2006 Blackwell Publishing, Inc. C 2006 International League Against Epilepsy The Outcome of Children with Intractable Seizures: A 3- to 6-Year Follow-up of 67 Children Who Remained

More information

Neurological Problems

Neurological Problems Neurological Problems Paediatric Palliative Care For Home Based Carers Funded by British High Commission, Pretoria Small Grant Scheme Neurological Problems The child s nervous system may be damaged through:

More information

roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd

roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Antonio Gil-Nagel. Programa de epilepsia Hospital Ruber Internacional, Madrid. Centro de Tecnología Biomédica Universidad Politécnica de Madrid

Antonio Gil-Nagel. Programa de epilepsia Hospital Ruber Internacional, Madrid. Centro de Tecnología Biomédica Universidad Politécnica de Madrid Antonio Gil-Nagel Programa de epilepsia Hospital Ruber Internacional, Madrid Centro de Tecnología Biomédica Universidad Politécnica de Madrid Prevalence of epilepsy: 8.93/1,000 (WHO 1 ) Europe population

More information

SHARED CARE GUIDELINE FOR MODAFINIL 1. Aim/Purpose of this Guideline. 2. The Guidance

SHARED CARE GUIDELINE FOR MODAFINIL 1. Aim/Purpose of this Guideline. 2. The Guidance SHARED CARE GUIDELINE FOR MODAFINIL 1. Aim/Purpose of this Guideline 1.1. This guideline applies to medical, nursing and pharmacy staff in the safe and appropriate prescription and administration of modafinil.

More information

Contemporary Developments in Childhood Epilepsy Management. Olivia O Mahony, Cork University Hospital, Cork, and Mercy University Hospital

Contemporary Developments in Childhood Epilepsy Management. Olivia O Mahony, Cork University Hospital, Cork, and Mercy University Hospital Contemporary Developments in Childhood Epilepsy Management Olivia O Mahony, Cork University Hospital, Cork, and Mercy University Hospital Developments in Epilepsy Care Standardised epilepsy care using

More information

Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures?

Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures? Słowińska et al. Orphanet Journal of Rare Diseases (2018) 13:25 DOI 10.1186/s13023-018-0764-z RESEARCH Open Access Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis

More information

Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults

Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHR Innovation Observatory Evidence Briefing: April 2017 Certolizumab pegol (Cimzia) for chronic plaque psoriasis in adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112 LAY SUMMARY Plaque psoriasis is the most

More information

Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340

Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 Ustekinumab for treating active psoriatic arthritis Technology appraisal guidance Published: 4 June 2015 nice.org.uk/guidance/ta340 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Canadian Expert Drug Advisory Committee Final Recommendation Plain Language Version

Canadian Expert Drug Advisory Committee Final Recommendation Plain Language Version Canadian Expert Drug Advisory Committee Final Recommendation Plain Language Version LACOSAMIDE (Vimpat UCB Canada Inc.) Indication: Epilepsy, Partial-Onset Seizures Recommendation: The Canadian Expert

More information

Ketogenic diet for epilepsy

Ketogenic diet for epilepsy Ketogenic diet for epilepsy Published Jun 24, 1998 Version 1 Findings by SBU Alert The ketogenic diet has been used for intractable epilepsy in children, and is a method that has been used sporadically

More information

The Changing Surgical Landscape in Kids

The Changing Surgical Landscape in Kids The Changing Surgical Landscape in Kids December 7, 2013 Howard L. Weiner, MD NYU Langone Medical Center American Epilepsy Society Annual Meeting Disclosure none American Epilepsy Society 2013 Annual Meeting

More information

Improving quality of care for epilepsy patients using a pharmacist review service

Improving quality of care for epilepsy patients using a pharmacist review service Improving quality of care for epilepsy patients using a pharmacist review service Carole Brown MSc (Clin Pharm), PIP, PwSI Epilepsy, MRPharmS A structured review process for epilepsy in primary care has

More information

Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review

Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review 641353TAU0010.1177/1756287216641353Therapeutic Advances in UrologyJJ Bissler and JC Kingswood research-article2016 Therapeutic Advances in Urology Review Optimal treatment of tuberous sclerosis complex

More information

Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008

More information

Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471

Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471 Eluxadoline for treating irritable bowel syndrome with diarrhoea Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta471 NICE 2017. All rights reserved. Subject to Notice of

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Technology Appraisals and Guidance Information Services Static List Review (SLR) Title and TA publication number of static topic: Final decision: TA82;

More information

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate

Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Clinical Commissioning Policy Proposition: Proton Beam Therapy for Cancer of the Prostate Reference: NHS England B01X09 First published: March 2016 Prepared by NHS England Specialised Services Clinical

More information

A Framework of Competences for Special Interest Module in Paediatric Epilepsies

A Framework of Competences for Special Interest Module in Paediatric Epilepsies A Framework of Competences for Special Interest Module in Paediatric Epilepsies 2 Section 1 CONTENTS Introduction 5 Section 2 Specific Competences in Paediatric Epilepsies 7 Knowledge and Understanding

More information

Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72

Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 Attention deficit hyperactivity disorder: diagnosis and management Clinical guideline Published: 24 September 2008 nice.org.uk/guidance/cg72 NICE 2018. All rights reserved. Subject to Notice of rights

More information

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials

DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials DRAFT (Final) Concept Paper On choosing appropriate estimands and defining sensitivity analyses in confirmatory clinical trials EFSPI Comments Page General Priority (H/M/L) Comment The concept to develop

More information

Benefits and risks of taking antiepileptic medicine for females Information for healthcare professionals

Benefits and risks of taking antiepileptic medicine for females Information for healthcare professionals Benefits and risks of taking antiepileptic medicine for females Information for healthcare professionals 2 Benefits and risks of taking antiepileptic medicine for females 3 This booklet provides information

More information

Summary Clinical Evaluation of Carisbamate for Adjunctive Use in Treatment of Partial Onset Seizures

Summary Clinical Evaluation of Carisbamate for Adjunctive Use in Treatment of Partial Onset Seizures Summary Clinical Evaluation of Carisbamate for Adjunctive Use in Treatment of Partial Onset Seizures J&J Pharmaceutical R&D Antiepileptic Drug Trials XI April 27 2011 Summary of Past Development Efficacy

More information

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440

Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440 Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440 NICE 2017. All rights reserved. Subject

More information

Evidence review for Surrey Prescribing Clinical Network SUMMARY

Evidence review for Surrey Prescribing Clinical Network SUMMARY East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Surrey Prescribing Clinical Network Medicine

More information

Surveillance report Published: 26 October 2017 nice.org.uk

Surveillance report Published: 26 October 2017 nice.org.uk Surveillance report 2017 Bipolar disorder: assessment and management (2014) NICE guideline Surveillance report Published: 26 October 2017 nice.org.uk NICE 2017. All rights reserved. Subject to Notice of

More information

Epilepsy 101. Russell P. Saneto, DO, PhD. Seattle Children s Hospital/University of Washington November 2011

Epilepsy 101. Russell P. Saneto, DO, PhD. Seattle Children s Hospital/University of Washington November 2011 Epilepsy 101 Russell P. Saneto, DO, PhD Seattle Children s Hospital/University of Washington November 2011 Specific Aims How do we define epilepsy? Do seizures equal epilepsy? What are seizures? Seizure

More information

p ผศ.นพ.ร งสรรค ช ยเสว ก ล คณะแพทยศาสตร ศ ร ราชพยาบาล

p ผศ.นพ.ร งสรรค ช ยเสว ก ล คณะแพทยศาสตร ศ ร ราชพยาบาล Natural Course and Prognosis of Epilepsy p ผศ.นพ.ร งสรรค ช ยเสว ก ล คณะแพทยศาสตร ศ ร ราชพยาบาล Introduction Prognosis of epilepsy generally means probability of being seizure-free after starting treatment

More information

Bevacizumab for the treatment of recurrent advanced ovarian cancer

Bevacizumab for the treatment of recurrent advanced ovarian cancer Bevacizumab for the treatment of recurrent advanced ovarian cancer ERRATUM This report was commissioned by the NIHR HTA Programme as project number 11/40 Page 2 This document contains errata in respect

More information

When to start, which drugs and when to stop

When to start, which drugs and when to stop When to start, which drugs and when to stop Dr. Suthida Yenjun, MD. PMK Epilepsy Annual Meeting 2016 The main factors to consider in making the decision The risk for recurrent seizures, which varies based

More information

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE

More information

Tuberous Sclerosis Complex: Rare Disease with Significant Social Impact (Case Series)

Tuberous Sclerosis Complex: Rare Disease with Significant Social Impact (Case Series) Original Articles 17 Tuberous Sclerosis Complex: Rare Disease with Significant Social Impact (Case Series) J. Breza jr. (Jan Breza jr.) 1, B. Novotna (Barbora Novotna) 2 Original Article 1 Department of

More information

Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta500

Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta500 Ceritinib for untreated ALK-positive non- small-cell lung cancer Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta500 NICE 2018. All rights reserved. Subject to Notice of

More information

Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200

Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200 NICE 2018. All rights reserved. Subject to

More information

Predictors of Intractable Childhood Epilepsy

Predictors of Intractable Childhood Epilepsy ORIGINAL ARTICLE Predictors of Intractable Childhood Epilepsy Muhammad Akbar Malik 1, Muhammad Haroon Hamid 2, Tahir Masood Ahmed 2 and Qurban Ali 3 ABSTRACT Objective: To determine the prognosis of seizures

More information

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481

Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 Immunosuppressive e therapy for kidney transplant in adults Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta481 NICE 2018. All rights reserved. Subject to Notice of rights

More information

Adult Psychiatric Morbidity Survey (APMS) 2014 Part of a national Mental Health Survey Programme

Adult Psychiatric Morbidity Survey (APMS) 2014 Part of a national Mental Health Survey Programme Adult Psychiatric Morbidity Survey (APMS) 2014 Part of a national Mental Health Survey Programme About the Adult Psychiatric Morbidity Survey (APMS) 2014 The Adult Psychiatric Morbidity Survey (APMS) 2014

More information

Physical health of children and adolescents

Physical health of children and adolescents Physical health of children and adolescents FR/CAP/02 What specialist child and adolescent psychiatrists need to know and do Faculty of Child and Adolescent Psychiatry, Royal College of Psychiatrists FACULTY

More information